TN2009000269A1 - Cycloalkylamine substituted isoquinolone derivatives - Google Patents

Cycloalkylamine substituted isoquinolone derivatives

Info

Publication number: TN2009000269A1
Authority: TN; Tunisia
Prior art keywords: isoquinolone derivatives; substituted isoquinolone; rho; cycloalkylamine; cycloalkylamine substituted
Prior art date: 2006-12-27

Application number

TNP2009000269A

Other languages

English (en)

Inventor

Olivier Plettenburg

Armin Hofmeister

Katrin Lorenz

Joachim Brendel

Matthias Lohn

John Weston

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-27

Filing date

2009-06-25

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38565513&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-06-25 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2010-10-18 Publication of TN2009000269A1 publication Critical patent/TN2009000269A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Virology (AREA)
Epidemiology (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)

TNP2009000269A 2006-12-27 2009-06-25 Cycloalkylamine substituted isoquinolone derivatives TN2009000269A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06026899		2006-12-27
PCT/EP2007/011164 WO2008077551A1 (fr)	2006-12-27	2007-12-19	Dérivés d'isoquinolone substitués par une cycloalkylamine

Publications (1)

Publication Number	Publication Date
TN2009000269A1 true TN2009000269A1 (en)	2010-10-18

Family

ID=38565513

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000269A TN2009000269A1 (en)	2006-12-27	2009-06-25	Cycloalkylamine substituted isoquinolone derivatives

Country Status (30)

Country	Link
US (1)	US8742116B2 (fr)
EP (1)	EP2125745B1 (fr)
JP (1)	JP5405314B2 (fr)
KR (1)	KR101474228B1 (fr)
CN (1)	CN101595094B (fr)
AR (1)	AR064492A1 (fr)
AU (1)	AU2007338407B2 (fr)
BR (1)	BRPI0722064A2 (fr)
CA (1)	CA2673917C (fr)
CL (1)	CL2007003821A1 (fr)
CO (1)	CO6210726A2 (fr)
CR (1)	CR10813A (fr)
DO (1)	DOP2009000164A (fr)
EC (1)	ECSP099467A (fr)
ES (1)	ES2625266T3 (fr)
GT (1)	GT200900179A (fr)
IL (1)	IL199540A (fr)
MA (1)	MA31075B1 (fr)
MX (1)	MX2009005966A (fr)
MY (1)	MY155009A (fr)
NI (1)	NI200900108A (fr)
NO (1)	NO20092422L (fr)
NZ (1)	NZ577980A (fr)
RU (1)	RU2457203C2 (fr)
SV (1)	SV2009003318A (fr)
TN (1)	TN2009000269A1 (fr)
TW (1)	TWI434689B (fr)
UY (1)	UY30843A1 (fr)
WO (1)	WO2008077551A1 (fr)
ZA (1)	ZA200903551B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101187612B1 (ko)	2003-04-09	2012-10-08	가부시키가이샤 니콘	노광 방법 및 장치, 그리고 디바이스 제조 방법
TWI628698B (zh)	2003-10-28	2018-07-01	尼康股份有限公司	照明光學裝置、曝光裝置、曝光方法以及元件製造方法
TW201809801A (zh)	2003-11-20	2018-03-16	日商尼康股份有限公司	光學照明裝置、曝光裝置、曝光方法、以及元件製造方法
TWI360837B (en)	2004-02-06	2012-03-21	Nikon Corp	Polarization changing device, optical illumination
ES2580108T3 (es)	2005-07-11	2016-08-19	Aerie Pharmaceuticals, Inc	Compuestos de isoquinolina
JP5235887B2 (ja)	2006-09-20	2013-07-10	アエリーファーマシューティカルズインコーポレイテッド	Ｒｈｏキナーゼ阻害剤
US8455513B2 (en)	2007-01-10	2013-06-04	Aerie Pharmaceuticals, Inc.	6-aminoisoquinoline compounds
US8455514B2 (en)	2008-01-17	2013-06-04	Aerie Pharmaceuticals, Inc.	6-and 7-amino isoquinoline compounds and methods for making and using the same
NZ590067A (en) *	2008-06-24	2012-09-28	Sanofi Aventis	Bi-and polycyclic substituted isoquinoline and isoquinolinone derivatives as rho kinase inhibitors
KR101607090B1 (ko) *	2008-06-24	2016-03-29	사노피	6-치환된 이소퀴놀린 및 이소퀴놀리논
ES2541827T3 (es) *	2008-06-24	2015-07-27	Sanofi	Isoquinolinas e isoquinolinonas sustituidas como inhibidores de Rho-cinasa
US8450344B2 (en)	2008-07-25	2013-05-28	Aerie Pharmaceuticals, Inc.	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2929545C (fr)	2009-05-01	2019-04-09	Aerie Pharmaceuticals, Inc.	Inhibiteurs a mecanisme double pour le traitement de maladie
CA2905089C (fr)	2013-03-15	2023-06-13	Aerie Pharmaceuticals, Inc.	Compose d'isoquinoline pour traiter des maladies oculaires
LT3057586T (lt)	2013-10-18	2020-03-10	Celgene Quanticel Research, Inc.	Bromodomeno inhibitoriai
US9902702B2 (en) *	2014-07-15	2018-02-27	Bristol-Myers Squibb Company	Spirocycloheptanes as inhibitors of rock
US9399194B2 (en) *	2014-07-16	2016-07-26	Battelle Energy Alliance, Llc	Methods for treating a liquid using draw solutions
AU2015371255B2 (en)	2014-12-24	2018-09-27	Gilead Sciences, Inc.	Fused pyrimidine compounds for the treatment of HIV
TW202237569A (zh)	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
EP3237397B1 (fr)	2014-12-24	2018-11-21	Gilead Sciences, Inc.	Composés isoindoline pour le traitement du vih
AR104259A1 (es)	2015-04-15	2017-07-05	Celgene Quanticel Res Inc	Inhibidores de bromodominio
CA3005707C (fr)	2015-11-17	2023-11-21	Aerie Pharmaceuticals, Inc.	Procede de preparation d'inhibiteurs de kinase et de leurs intermediaires
US9643927B1 (en)	2015-11-17	2017-05-09	Aerie Pharmaceuticals, Inc.	Process for the preparation of kinase inhibitors and intermediates thereof
UY37073A (es) *	2016-01-13	2017-07-31	Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware	Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
RS63240B1 (sr)	2016-02-12	2022-06-30	Cytokinetics Inc	Derivati tetrahidroizohinolina
AU2017252276A1 (en)	2016-04-18	2018-11-15	Celgene Quanticel Research, Inc.	Therapeutic compounds
US10150754B2 (en)	2016-04-19	2018-12-11	Celgene Quanticel Research, Inc.	Histone demethylase inhibitors
CA3030283A1 (fr)	2016-07-08	2018-01-11	Rigel Pharmaceuticals, Inc.	Inhibiteurs de la tyrosine kinase
WO2018045091A1 (fr)	2016-08-31	2018-03-08	Aerie Pharmaceuticals, Inc.	Compositions ophtalmiques
KR20190135027A (ko)	2017-03-31	2019-12-05	에어리 파마슈티컬즈, 인코포레이티드	아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
US12060341B2 (en)	2017-07-12	2024-08-13	Bristol-Myers Squibb Company	Spiroheptanyl hydantoins as ROCK inhibitors
US11447487B2 (en)	2017-07-12	2022-09-20	Bristol-Myers Squibb Company	Spiroheptanyl hydantoins as rock inhibitors
CA3112391A1 (fr)	2018-09-14	2020-03-19	Aerie Pharmaceuticals, Inc.	Composes d'amide aryl cyclopropyl-amino-isoquinolinyl
US11351149B2 (en)	2020-09-03	2022-06-07	Pfizer Inc.	Nitrile-containing antiviral compounds
AR125196A1 (es)	2021-03-26	2023-06-21	Novartis Ag	Derivados de ciclobutilo 1,3-sustituidos y sus usos

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2485537B2 (fr)	1977-04-13	1986-05-16	Anvar	Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
WO1992002476A1 (fr)	1990-07-31	1992-02-20	E.I. Du Pont De Nemours And Company	Equilibrage catalytique d'halocarbones selectionnes
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5731324A (en) *	1993-07-22	1998-03-24	Eli Lilly And Company	Glycoprotein IIb/IIIa antagonists
US5843943A (en) *	1994-12-29	1998-12-01	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
GB9516709D0 (en)	1995-08-15	1995-10-18	Zeneca Ltd	Medicament
ZA9610741B (en)	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
IL128456A0 (en)	1996-08-12	2000-01-31	Yoshitomi Pharmaceutical	Compositions containing a Rho kinase inhibitor
JP2852649B2 (ja)	1997-03-19	1999-02-03	チッソ株式会社	ポリイミド系硬化膜
AU8872198A (en)	1997-08-29	1999-03-22	Zeneca Limited	Aminometyl oxooxazolidinyl benzene derivatives
TW575567B (en)	1998-10-23	2004-02-11	Akzo Nobel Nv	Serine protease inhibitor
GB9912701D0 (en)	1999-06-01	1999-08-04	Smithkline Beecham Plc	Novel compounds
US6541456B1 (en)	1999-12-01	2003-04-01	Isis Pharmaceuticals, Inc.	Antimicrobial 2-deoxystreptamine compounds
NZ520041A (en)	2000-01-20	2004-11-26	Eisai Co Ltd	Novel piperidine compounds and drugs containing the same
US7217722B2 (en) *	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en)	2000-02-29	2001-09-12	Curis, Inc.	Methods and compositions for regulating adipocytes
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en)	2000-05-31	2000-07-19	Astrazeneca Ab	Chemical compounds
WO2002034712A1 (fr)	2000-10-27	2002-05-02	Takeda Chemical Industries, Ltd.	Procede de preparation de composes aromatiques substitues et produits intermediaires associes
WO2002055496A1 (fr)	2001-01-15	2002-07-18	Glaxo Group Limited	Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
SE0101038D0 (sv)	2001-03-23	2001-03-23	Astrazeneca Ab	Novel compounds
US20030095958A1 (en)	2001-04-27	2003-05-22	Bhisetti Govinda R.	Inhibitors of bace
JPWO2002100833A1 (ja)	2001-06-12	2004-09-24	住友製薬株式会社	Ｒｈｏキナーゼ阻害剤
GB0117899D0 (en)	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
WO2003024450A1 (fr)	2001-09-20	2003-03-27	Eisai Co., Ltd.	Methodes de traitement des maladies a prions
SE0104340D0 (sv)	2001-12-20	2001-12-20	Astrazeneca Ab	New compounds
AU2003281623B8 (en)	2002-07-22	2009-06-11	Asahi Kasei Pharma Corporation	5-substituted isoquinoline derivative
CA2502583A1 (fr)	2002-09-12	2004-03-25	Kirin Beer Kabushiki Kaisha	Derives d'isoquinoline d'inhibition des kinases et medicaments contenant ceux-ci
WO2004106325A1 (fr)	2003-05-29	2004-12-09	Schering Aktiengesellschaft	Promedicaments de 1-(1-hydroxy-5-isoquinolinesulfonyl)homopiperazine
WO2004113297A2 (fr)	2003-06-24	2004-12-29	Neurosearch A/S	Derives de noyaux aza et utilisation de ceux-ci comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
AU2004275720B2 (en)	2003-09-23	2008-04-24	Merck Sharp & Dohme Corp.	Isoquinoline potassium channel inhibitors
WO2005030791A2 (fr)	2003-09-23	2005-04-07	Merck & Co., Inc.	Inhibiteurs du canal potassique d'isoquinolinone
US20050067037A1 (en)	2003-09-30	2005-03-31	Conocophillips Company	Collapse resistant composite riser
WO2005035516A1 (fr)	2003-10-10	2005-04-21	Ono Pharmaceutical Co., Ltd.	Nouveau compose heterocyclique fondu et utilisation correspondante
US7449477B2 (en)	2003-11-25	2008-11-11	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
JP2005232175A (ja) *	2004-01-21	2005-09-02	Asahi Kasei Pharma Kk	５−置換イソキノリン医薬
WO2005074535A2 (fr)	2004-01-30	2005-08-18	Eisai Co., Ltd.	Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
TW200536830A (en) *	2004-02-06	2005-11-16	Chugai Pharmaceutical Co Ltd	1-(2H)-isoquinolone derivative
US20080312189A1 (en)	2004-03-05	2008-12-18	Eisai Co., Ltd.	Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv)	2004-03-30	2004-03-31	Astrazeneca Ab	Novel Compounds
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
CA2615663C (fr)	2005-07-26	2013-10-15	Sanofi-Aventis	Derives de la cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rho-kinase
PT1910333E (pt)	2005-07-26	2013-08-01	Sanofi Sa	Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
TW200745101A (en)	2005-09-30	2007-12-16	Organon Nv	9-Azabicyclo[3.3.1]nonane derivatives
US7618985B2 (en)	2005-12-08	2009-11-17	N.V. Organon	Isoquinoline derivatives
TW200738682A (en)	2005-12-08	2007-10-16	Organon Nv	Isoquinoline derivatives
US7893088B2 (en)	2006-08-18	2011-02-22	N.V. Organon	6-substituted isoquinoline derivatives
WO2008077555A2 (fr)	2006-12-27	2008-07-03	Sanofi-Aventis	Nouveaux dérivés d'isoquinoline et d'isoquinolinone substitués
BRPI0720859A2 (pt)	2006-12-27	2014-03-25	Sanofi Aventis	Derivados de isoquinolina e isoquinolinona substituídos com cicloalquilamina

2007
- 2007-12-19 EP EP07856887.0A patent/EP2125745B1/fr active Active
- 2007-12-19 AU AU2007338407A patent/AU2007338407B2/en not_active Ceased
- 2007-12-19 BR BRPI0722064-2A2A patent/BRPI0722064A2/pt not_active IP Right Cessation
- 2007-12-19 MX MX2009005966A patent/MX2009005966A/es active IP Right Grant
- 2007-12-19 JP JP2009543372A patent/JP5405314B2/ja not_active Expired - Fee Related
- 2007-12-19 WO PCT/EP2007/011164 patent/WO2008077551A1/fr not_active Ceased
- 2007-12-19 KR KR1020097013520A patent/KR101474228B1/ko not_active Expired - Fee Related
- 2007-12-19 CN CN2007800485284A patent/CN101595094B/zh not_active Expired - Fee Related
- 2007-12-19 ES ES07856887.0T patent/ES2625266T3/es active Active
- 2007-12-19 RU RU2009128653/04A patent/RU2457203C2/ru not_active IP Right Cessation
- 2007-12-19 NZ NZ577980A patent/NZ577980A/en not_active IP Right Cessation
- 2007-12-19 CA CA2673917A patent/CA2673917C/fr not_active Expired - Fee Related
- 2007-12-19 MY MYPI20092589A patent/MY155009A/en unknown
- 2007-12-21 AR ARP070105857A patent/AR064492A1/es unknown
- 2007-12-25 TW TW096149803A patent/TWI434689B/zh active
- 2007-12-26 UY UY30843A patent/UY30843A1/es unknown
- 2007-12-26 CL CL2007003821A patent/CL2007003821A1/es unknown
2009
- 2009-05-20 CR CR10813A patent/CR10813A/es not_active Application Discontinuation
- 2009-05-22 ZA ZA200903551A patent/ZA200903551B/xx unknown
- 2009-06-02 NI NI200900108A patent/NI200900108A/es unknown
- 2009-06-16 CO CO09062108A patent/CO6210726A2/es not_active Application Discontinuation
- 2009-06-18 US US12/487,479 patent/US8742116B2/en not_active Expired - Fee Related
- 2009-06-24 IL IL199540A patent/IL199540A/en not_active IP Right Cessation
- 2009-06-24 MA MA32036A patent/MA31075B1/fr unknown
- 2009-06-24 GT GT200900179A patent/GT200900179A/es unknown
- 2009-06-24 SV SV2009003318A patent/SV2009003318A/es unknown
- 2009-06-25 NO NO20092422A patent/NO20092422L/no not_active Application Discontinuation
- 2009-06-25 TN TNP2009000269A patent/TN2009000269A1/fr unknown
- 2009-06-26 DO DO2009000164A patent/DOP2009000164A/es unknown
- 2009-06-26 EC EC2009009467A patent/ECSP099467A/es unknown

Also Published As

Publication number	Publication date
IL199540A (en)	2015-05-31
MA31075B1 (fr)	2010-01-04
RU2009128653A (ru)	2011-02-10
RU2457203C2 (ru)	2012-07-27
HK1139390A1 (en)	2010-09-17
KR101474228B1 (ko)	2014-12-18
US20100056518A1 (en)	2010-03-04
CA2673917C (fr)	2015-01-27
NO20092422L (no)	2009-09-25
TW200843768A (en)	2008-11-16
SV2009003318A (es)	2010-02-05
NZ577980A (en)	2012-01-12
AR064492A1 (es)	2009-04-08
ZA200903551B (en)	2010-03-31
MY155009A (en)	2015-08-28
ECSP099467A (es)	2009-07-31
EP2125745B1 (fr)	2017-02-22
MX2009005966A (es)	2009-06-15
UY30843A1 (es)	2008-07-31
CA2673917A1 (fr)	2008-07-03
GT200900179A (es)	2010-07-02
CO6210726A2 (es)	2010-10-20
JP5405314B2 (ja)	2014-02-05
AU2007338407B2 (en)	2012-08-02
WO2008077551A1 (fr)	2008-07-03
NI200900108A (es)	2010-01-15
DOP2009000164A (es)	2009-08-15
CN101595094B (zh)	2013-02-20
CN101595094A (zh)	2009-12-02
AU2007338407A1 (en)	2008-07-03
EP2125745A1 (fr)	2009-12-02
ES2625266T3 (es)	2017-07-19
US8742116B2 (en)	2014-06-03
JP2010514716A (ja)	2010-05-06
KR20090102775A (ko)	2009-09-30
CL2007003821A1 (es)	2009-10-16
CR10813A (es)	2009-08-12
TWI434689B (zh)	2014-04-21
BRPI0722064A2 (pt)	2014-04-01

Publication	Publication Date	Title
TN2009000269A1 (en)	2010-10-18	Cycloalkylamine substituted isoquinolone derivatives
MX2009005967A (es)	2009-06-15	Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina.
MY151953A (en)	2014-07-31	Cycloalkylamine substituted isoquinoline derivatives
MY148514A (en)	2013-04-30	Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
TN2009000273A1 (en)	2010-10-18	New substituted isoquinoline and isoquinolinone derivatives
MY155279A (en)	2015-09-30	Substituted isoquinoline and isoquinolinone derivatives
MY150746A (en)	2014-02-28	Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
TNSN08039A1 (en)	2009-07-14	Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
TW200738678A (en)	2007-10-16	Isoquinoline derivatives
TNSN08038A1 (en)	2009-07-14	Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
AU2009262516A8 (en)	2014-01-30	6-substituted isoquinolines and isoquinolinones
TN2010000588A1 (en)	2012-05-24	Substituted isoquinolines and isoquinolinones